$MCK

CD&R And McKesson To Acquire Option Care Health

CD&R and McKesson (MCK) will acquire Option Care Health (OPCH) for $32.05 per share, valuing the deal at $5.8 billion. CD&R will hold 51% and McKesson 49%. Option Care will become private. OPCH shares rose 20.5% in pre-market trading.

Original reporting
Published Oct 6, 2026, 12:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 2:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$MCK
Neutral
high confidence
Mentioned
$MCK · $OPCH
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$MCKNeutralHigh
01

Why it matters

The transaction creates a new joint venture with CD&R holding 51% and McKesson 49%, positioning the combined entity for growth in the expanding home‑care market.

02

Market read

First‑report of a $5.8 bn M&A deal in the healthcare services sector, triggering a notable pre‑market rally in the target’s stock.

03

What to watch

Regulatory approval timelines and potential antitrust scrutiny could delay closing.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

CD&R, a private‑equity firm, partners with McKesson to acquire Option Care Health, a provider of home infusion services.

Company-level read

Ticker impact

$MCKNeutralHigh confidence
Context

McKesson is a co‑buyer in the $5.8 bn acquisition of Option Care Health, committing $1.4 bn for a 49% stake.

Expected impact

likely modest pressure as investors assess the $1.4 bn investment cost

Evidence & confidence

The deal size is material and disclosed for the first time; market will price the financing impact.

$OPCHBullishHigh confidence
Context

Option Care Health is being acquired and its shares jumped 20.5% pre‑market to $28.16 on the announcement.

Expected impact

upward pressure as the premium is priced in

Evidence & confidence

First‑report of the deal and a 20% price jump indicate strong immediate buying interest.

Market effects

Consolidates the home‑infusion market and may spur further M&A activity in healthcare services.

U.S. healthcare sector gains visibility; no immediate global ripple.

Limited to U.S. healthcare investors; the deal size is notable but not systemic.

Counterpoint

The premium may be excessive; integration risks could erode value for McKesson.

Key entities

  • CD&R

    Co‑buyer holding 51% of the post‑deal entity.

  • McKesson Corp.

    U.S. healthcare distributor acquiring a 49% stake for $1.4 bn.

  • Option Care Health

    Target of the acquisition; shares rose 20.5% on news.

Related articles

$OPCHHighAI 9/10

Infusion therapy provider being acquired in $5.8 billion deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson in a $5.8 billion deal, expected to close in early 2027. CD&R will hold majority ownership, with McKesson holding a minority stake. Option Care Health shares were trading at $31.02, up from $23.34 before the acquisition news. The company will remain separate but will delist from Nasdaq post-deal.

$OPCHHighAI 9/10

Option Care stock surges on McKesson's home-infusion bet

Option Care Health (OPCH) shares rose 33% to $31.11 after McKesson (MCK) and Clayton, Dubilier & Rice agreed to take it private for $32.05 per share, valuing it at $5.8B. McKesson will initially own 49%, with an option to acquire the rest later. The deal gives McKesson access to Option Care's home-infusion network, serving 315K+ patients. Option Care's Q2 revenue grew 1.9% to $1.44B. The deal needs shareholder and regulatory approvals to close in early 2027.

$MCKHighAI 9/10

McKesson Plans $1.4 Billion Stake in $5.8 Billion Option Care Buyout

McKesson plans a $1.4B investment for a 49% stake in Option Care Health, part of a $5.8B buyout by Clayton, Dubilier & Rice. Shareholders will receive $32.05 per share. The deal, pending approvals, is expected to close in early 2027. Option Care shares rose 32.7% on the news. McKesson's Q1 revenue grew 8% to $105.4B, with net income down 22% to $614M.